Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hochhaus

Showing results (1-10 of 216) with videos related to

Pageof 22
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2006
Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitorsA Hochhaus
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Advances in the treatment of haematological malignancies: optimal sequence of CML treatmentA Hochhaus
Deutsche Medizinische Wochenschrift (1946)|October 1, 2011
[Chronic myeloid leukemia]A Hochhaus
Leukemia|October 17, 2003
A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reachedA Hochhaus
Annals of Hematology|May 6, 2004
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST)A Hochhaus
Deutsche Medizinische Wochenschrift (1946)|March 1, 2002
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease]A Hochhaus
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2008
Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-upA Hochhaus, M Dreyling,
Der Pathologe|August 29, 2015
[Acute leukemia in adults]E Eigendorff, A Hochhaus
Leukemia|June 13, 2020
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammationF Heidel, A Hochhaus
Der Internist|October 1, 1996
[Chronic myeloid leukemia. Current strategies in diagnosis, therapy and follow-up]A Hochhaus, R Hehlmann
Pageof 22

Showing results (1-10 of 216) with videos related to

Sort By:
Pageof 22
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2006
Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitorsA Hochhaus
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Advances in the treatment of haematological malignancies: optimal sequence of CML treatmentA Hochhaus
Deutsche Medizinische Wochenschrift (1946)|October 1, 2011
[Chronic myeloid leukemia]A Hochhaus
Leukemia|October 17, 2003
A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reachedA Hochhaus
Annals of Hematology|May 6, 2004
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST)A Hochhaus
Deutsche Medizinische Wochenschrift (1946)|March 1, 2002
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease]A Hochhaus
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2008
Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-upA Hochhaus, M Dreyling,
Der Pathologe|August 29, 2015
[Acute leukemia in adults]E Eigendorff, A Hochhaus
Leukemia|June 13, 2020
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammationF Heidel, A Hochhaus
Der Internist|October 1, 1996
[Chronic myeloid leukemia. Current strategies in diagnosis, therapy and follow-up]A Hochhaus, R Hehlmann
Pageof 22